Incidence of ocular pathology following bariatric surgery for with morbid obesity across a large United States National Database
- PMID: 38678114
- PMCID: PMC11385951
- DOI: 10.1038/s41433-024-03088-z
Incidence of ocular pathology following bariatric surgery for with morbid obesity across a large United States National Database
Abstract
Background/objectives: Bariatric surgery, as indicated for treatment of morbid obesity, has been studied in association with short term effects on ocular pathology. However, effects of surgery on postoperative disease incidence is largely unknown.
Subjects/methods: In this retrospective cohort study, the TriNetX United States Collaborative Network national database, was queried for patients with an ICD-10 code for morbid obesity and a procedural code for bariatric surgery. Patients were propensity score matched across baseline demographics at the time of surgery and compared to those presenting with an ICD10 code for morbid obesity with no records of a procedural code for bariatric surgery, identifying 42,408 patients per cohort. New diagnoses or procedural codes found after the surgical index date for diabetic retinopathy, age-related macular degeneration, glaucoma, low vision, and blindness along with pertinent treatment metrics were monitored.
Results: Bariatric surgery was found to be associated with reduced future risk of diabetic retinopathy (RR: 0.283; 95% CI: 0.252-0.319), macular edema (RR: 0.224; 95% CI: 0.170-0.297), vitreous hemorrhage (RR: 0.459; 95% CI: 0.323-0.653), ocular hypertension (RR: 0.387; 95% CI: 0.387-0.487), glaucoma (RR: 0.360; 95% CI: 0.326-0.399), use of ocular pressure lowering medications (RR: 0.565; 95% CI: 0.496-0.644), age-related macular degeneration (RR: 0.628; 95% CI: 0.447-0.882), cataract surgery (RR: 0.524; 95% CI: 0.448-0.612), and low vision and blindness (RR: 0.328; 95% CI: 0.294-0.365) compared to patients not surgically managed.
Conclusions: The present analysis comprising a large US cohort of patients suggests that bariatric surgery is associated with a decreased risk of future ocular morbidity and mortality.
© 2024. The Author(s).
Conflict of interest statement
KET reports research grants from Zeiss and Regenxbio, speaker fees from Genentech, and consulting fees from Genentech, Apellis and Eyepoint. RPS reports personal fees from Genentech/Roche, personal fees from Alcon/Novartis, grants from Apellis and Graybug, personal fees from Zeiss, personal fees from Bausch + Lomb, personal fees from Regeneron Pharmaceuticals, Inc. Inc. All other authors report no disclosures.
References
-
- Stahl JM, Malhotra S. Obesity Surgery Indications And Contraindications. StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK513285/. Accessed 24 October 2022. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical